Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus

Journal of Virology

Volumn 86, Issue 13, 2012, Pages 7310-7325

  Duraffour, Sophie ^a   Andrei, Graciela ^a   Topalis, Dimitri ^a   Krečmerová, Marcela ^b   Crance, Jean Marc ^c   Garin, Daniel ^c,d   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c IRBA   (France)

^d Ecole du Val de Grace   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 HYDROXY 2 OXIDO 1,4,2 DIOXAPHOSPHINAN 5 YL)METHYL] 5 AZACYTOSINE; 1 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 5 AZACYTOSINE; 2,4 DIAMINO 6 [2 (PHOSPHONOMETHOXY)ETHOXY]PYRIMIDINE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 2,6 DIAMINOPURINE; [2,4 DIAMINO 3 HYDROXY 6 [2 (PHOSPHONOMETHOXY)PROPOXY]]PYRIMIDINE; ACYCLIC NUCLEOSIDE; ALANINE; ANTIVIRUS AGENT; CIDOFOVIR; DNA POLYMERASE; ISOLEUCINE; PHOSPHONIC ACID DERIVATIVE; THREONINE; UNCLASSIFIED DRUG; VALINE; VIRUS ENZYME;

AMINO ACID ANALYSIS; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIVIRAL RESISTANCE; ARTICLE; CAMELPOX VIRUS; CONTROLLED STUDY; CROSS RESISTANCE; DNA POLYMERASE GENE; DNA STRAND; FEMALE; GENE MUTATION; GENE SEQUENCE; GROWTH INHIBITION; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ORTHOPOXVIRUS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; VACCINIA VIRUS; VIRUS GENE; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CYTOSINE; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MUTANT PROTEINS; MUTATION, MISSENSE; ORTHOPOXVIRUS; PHOSPHONIC ACIDS; RECOMBINANT PROTEINS; SELECTION, GENETIC; VACCINIA VIRUS; VIRAL PLAQUE ASSAY;

CAMELPOX VIRUS; ORTHOPOXVIRUS; VACCINIA VIRUS;

EID: 84864121170     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00355-12     Document Type: Article

References (66)

1. Abrahao JS, et al. 2010. Vaccinia virus infection in monkeys, Brazilian Amazon. Emerg. Infect. Dis. 16:976 -979.
2. Afonso CL, et al. 2002. The genome of camelpox virus. Virology 295:1-9.
3. Andrei G, et al. 2007. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drugenzyme interactions. Antivir. Ther. 12:719 -732.
4. Andrei G, et al. 2006. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 80:9391-9401.
5. Andrei G, et al. 2000. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J. Gen. Virol. 81:639-648.
6. Anonymous. 2007. Household transmission of vaccinia virus from contact with a military smallpox vaccinee-Illinois and Indiana, 2007.MMWR Morb. Mortal. Wkly. Rep. 56:478-481.
7. Anonymous. 2009. Progressive vaccinia in a military smallpox vaccinee- United States, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:532-536.
8. Anonymous. 2010. FDA Fast Track status for IMVAMUNE. Hum. Vaccines 6:5.
9. Becker C, et al. 2009. Cowpox virus infection in pet rat owners: not always immediately recognized. Dtsch. Arztebl. Int. 106:329 -334.
10. Becker MN, et al. 2008. Isolation and characterization of cidofovirresistant vaccinia viruses. Virol. J. 5:58.
11. Bera BC, et al. 2011. Zoonotic cases of camelpox infection in India. Vet. Microbiol. 152:29 -38.
12. Berdis AJ. 2008. DNA polymerases as therapeutic targets. Biochemistry 47:8253- 8260.
13. Bhanuprakash V, et al. 2010. Zoonotic infections of buffalopox in India. Zoonoses. Public Health 57:e149-e155.
14. Bolden A, Aucker J, Weissbach A. 1975. Synthesis of herpes-simplex virus, vaccinia virus, and adenovirus DNA in isolated HeLa-cell nuclei. 1. Effect of viral-specific antisera and phosphonoacetic acids. J. Virol. 16: 1584-1592.
15. Boyle KA, Stanitsa ES, Greseth MD, Lindgren JK, Traktman P. 2011. Evaluation of the role of the vaccinia virus uracilDNAglycosylase and A20 proteins as intrinsic components of the DNA polymerase holoenzyme. J. Biol. Chem. 286:24702-24713.
16. Dal Pozzo F, et al. 2005. Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures. Antimicrob. Agents Chemother. 49:4843- 4852.
17. Dal Pozzo F, et al. 2007. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antivir. Res. 75:52-57.
18. Damon I. 2007. Poxviruses, p 2947-2975. In Knipe DM, HowleyPM(ed), Fields virology, 4th ed. Lippincott/The Williams & Wilkins Co, Philadelphia, PA.
19. De Clercq E. 2008. The discovery of antiviral agents: ten different compounds, ten different stories. Med. Res. Rev. 28:929 -953.
20. De Clercq E. 2009. Another ten stories in antiviral drug discovery (part C): " old" and " new" antivirals, strategies, and perspectives. Med. Res. Rev. 29:611- 645.
21. De Clercq E. 2009. Antiviral drug discovery: ten more compounds, and ten more stories (part B). Med. Res. Rev. 29:571- 610.
22. De Clercq E. 2010. Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductions. Med. Res. Rev. 30:667- 707.
23. De Clercq E. 2011. The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures. Med. Res. Rev. 31:118 -160.
24. De Clercq E, et al. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antivir. Res. 8:261-272.
25. Dina J, et al. 2011. Genital ulcerations due to a cowpox virus: a misleading diagnosis of herpes. J. Clin. Virol. 50:345-347.
26. Duraffour S, et al. 2011. Study of camelpox virus pathogenesis in athymic nude mice. PLoS One 6:e21561. doi:10.1371/journal.pone.0021561.
27. Duraffour S, et al. 2007. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox, and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir. Ther. 12:1205-1216.
28. Duraffour S, et al. 2007. Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models. Antimicrob. Agents Chemother. 51:4410-4419.
29. Duraffour S, et al. 2008. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently. Antivir. Ther. 13:977-990.
30. Farlow J, Ichou MA, Huggins J, Ibrahim S. 2010. Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus. Virol. J. 7:110.
31. Gammon DB, Evans DH. 2009. The 3'-to-5' exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination. J. Virol. 83:4236-4250.
32. Gammon DB, et al. 2008. Mechanism of antiviral drug resistance of vaccinia virus: identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs. J. Virol. 82:12520- 12534.
33. Gubser C, Smith GL. 2002. The sequence of camelpox virus shows it is most closely related to variola virus, the cause of smallpox. J. Gen. Virol. 83:855- 872.
34. Gurav YK, et al. 2011. Buffalopox outbreak in humans and animals in Western Maharashtra, India. Prev. Vet. Med. 100:242-247.
35. Haase O, et al. 2011. Generalized cowpox infection in a patient with Darier disease. Br. J. Dermatol. 164:1116 -1118.
36. Hemmer CJ, et al. 2010. Human cowpox virus infection acquired from a circus elephant in Germany. Int. J. Infect. Dis. 14(Suppl 3):e338-e340.
37. Herman BD, Votruba I, Holy A, Sluis-Cremer N, Balzarini J. 2010. The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization. J. Biol. Chem. 285:12101-12108.
38. Hogg M, Wallace SS, Doublie S. 2004. Crystallographic snapshots of a replicative DNA polymerase encountering an abasic site. EMBO J. 23: 1483-1493.
39. Holy A, et al. 2002. 6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. J. Med. Chem. 45:1918 -1929.
40. Jordan R, Hruby D. 2006. Smallpox antiviral drug development: satisfying the animal efficacy rule. Expert Rev. Anti-Infect. Ther. 4:277-289.
41. Kaiser J. 2007. Smallpox vaccine: a tame virus runs amok. Science 316: 1418-1419.
42. Kern ER, et al. 2002. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob. Agents Chemother. 46:991-995.
43. Kornbluth RS, et al. 2006. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother. 50:4038-4043.
44. Krecmerova M, et al. 2007. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. J. Med. Chem. 50:1069 -1077.
45. Lanier R, et al. 2010. Development of CMX001 for the treatment of poxvirus infections. Viruses 2:2740 -2762.
46. Lebeau I, et al. 2007. Inhibitory activities of three classes of acyclic nucleoside phosphonates against murine polyomavirus and primate simian virus 40 strains. Antimicrob. Agents Chemother. 51:2268 -2273.
47. Magee WC, Aldern KA, Hostetler KY, Evans DH. 2008. Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand. Antimicrob. Agents Chemother. 52:586 -597.
48. Magee WC, Hostetler KY, Evans DH. 2005. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 49:3153-3162.
49. Mancaux J, Vervel C, Bachour N, Domart Y, Emond JP. 2011. Necrotic skin lesions caused by pet rats in two teenagers. Arch. Pediatr. 18:160 -164. (In French.)
50. Marris E. 2007. Dramatic rescue relieves rare case of smallpox infection. Nat. Med. 13:517.
51. Moss B. 2007. Poxviridae: the viruses and their replication, p 2905-2945. In Knipe DM, Howley PM (ed), Fields virology, 5th ed, vol 2. Lippincott/ The Williams & Wilkins Co, Philadelphia, PA.
52. Papanicolaou G, et al. 2011. CMX001 is not nephrotoxic or myelosuppressive in 183 patients with life-threatening dsDNA infections including refractory cytomegalovirus, adenovirus, and BK virus, abstr. V-499b. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother.
53. Pfeffer M, Meyer H, Wernery U, Kaaden OR. 1996. Comparison of camelpox viruses isolated in Dubai. Vet. Microbiol. 49:135-146.
54. Ramyar H, Hessami M. 1972. Isolation, cultivation, and characterization of camel pox virus. Zentralbl. Veterinarmed. B 19:182-189.
55. Rimoin AW, et al. 2010. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc. Natl. Acad. Sci. U. S. A. 107:16262-16267.
56. Silva DC, Moreira-Silva EA, Gomes JA, Fonseca FG, Correa-Oliveira R. 2010. Clinical signs, diagnosis, and case reports of vaccinia virus infections. Braz. J. Infect. Dis. 14:129 -134.
57. Smee DF. 2008. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir. Chem. Chemother. 19:115-124.
58. Smee DF, Bailey KW, Wong MH, Tarbet EB. 2011. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances. Antivir. Chem. Chemother. 21:201- 208.
59. Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW. 2002. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46:1329 -1335.
60. Smee DF, et al. 2005. Characterization and treatment of cidofovirresistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir. Chem. Chemother. 16:203-211.
61. Snoeck R, et al. 2002. Anti-vaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob. Agents Chemother. 46:3356 -3361.
62. Stanitsa ES, Arps L, Traktman P. 2006. Vaccinia virus uracil DNA glycosylase interacts with the A20 protein to form a heterodimeric processivity factor for the viral DNA polymerase. J. Biol. Chem. 281:3439 -3451.
63. Stittelaar KJ, et al. 2006. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439:745- 748.
64. von Bomhard W, Mauldin EA, Breuer W, Pfleghaar S, Nitsche A. 2010. Localized cowpox infection in a 5-month-old Rottweiler. Vet. Dermatol. 22:111-114.
65. von Krempelhuber A, et al. 2010. A randomized, double-blind, dosefinding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 28:1209- 1216.
66. Yang G, et al. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139 -13149.